A61K 39/385
Haptens or antigens, bound to carriers
A61K39/385 (Haptens or antigens, bound to carriers) appears on 1,088 US grants and 1,894 published applications in this corpus.
Search patents in A61K- Granted patents
- 1,088
- Published applications
- 1,894
- Assignees
- 914
- Inventors
- 3,489
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1977 | 2 | 0 |
| 1978 | 0 | 0 |
| 1979 | 1 | 0 |
| 1980 | 3 | 0 |
| 1981 | 4 | 0 |
| 1982 | 1 | 0 |
| 1983 | 3 | 0 |
| 1984 | 7 | 0 |
| 1985 | 3 | 0 |
| 1986 | 5 | 0 |
| 1987 | 8 | 0 |
| 1988 | 3 | 0 |
| 1989 | 6 | 0 |
| 1990 | 4 | 0 |
| 1991 | 5 | 0 |
| 1992 | 7 | 0 |
| 1993 | 4 | 0 |
| 1994 | 5 | 0 |
| 1995 | 4 | 0 |
| 1996 | 7 | 0 |
| 1997 | 7 | 0 |
| 1998 | 12 | 0 |
| 1999 | 20 | 0 |
| 2000 | 17 | 0 |
| 2001 | 13 | 3 |
| 2002 | 13 | 40 |
| 2003 | 17 | 62 |
| 2004 | 13 | 52 |
| 2005 | 11 | 44 |
| 2006 | 20 | 43 |
| 2007 | 19 | 55 |
| 2008 | 22 | 61 |
| 2009 | 30 | 70 |
| 2010 | 22 | 66 |
| 2011 | 28 | 70 |
| 2012 | 37 | 73 |
| 2013 | 36 | 78 |
| 2014 | 54 | 75 |
| 2015 | 51 | 101 |
| 2016 | 62 | 89 |
| 2017 | 60 | 88 |
| 2018 | 60 | 91 |
| 2019 | 62 | 82 |
| 2020 | 55 | 64 |
| 2021 | 58 | 89 |
| 2022 | 39 | 64 |
| 2023 | 41 | 101 |
| 2024 | 54 | 93 |
| 2025 | 47 | 126 |
| 2026 | 26 | 114 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Nanomaterials comprising acetals6 Oct 2026US 12,753,147 B2Beam Therapeutics Inc.
- Long-acting spleen-targeting cationic lipid compound comprising benzene ring structure, composition comprising same, and use thereof22 Sep 2026US 12,741,930 B2Beijing Youcare Kechuang Pharmaceutical Technology Co., Ltd.
- Production of MHC II/CII complexes1 Sep 2026US 12,721,884 B2
- Spleen-targeted ionizable lipid compound, composition comprising same and use thereof1 Sep 2026US 12,723,016 B2Beijing Carrius Bio Ltd.
- Nitrogen-branched non-linear pegylated lipid containing a tertiary amine and application thereof18 Aug 2026US 12,708,675 B2Xiamen Sinopeg Biotech Co., Ltd.
- Development of carbohydrate-based anti-salmonella vaccines8 Oct 2026US 2026/0306602 A1Board of Trustees of Michigan State University
- Vaccine Adjuvants8 Oct 2026US 2026/0306623 A1Seqirus Inc.
- Programmably degradable hydrogels for functional molecular release1 Oct 2026US 2026/0294805 A1Georgia Tech Research Corporation
- Protein-based drug products using monoester-free polysorbate detergent1 Oct 2026US 2026/0294831 A1Novavax, Inc.
- Improved alum-anchored immunogens1 Oct 2026US 2026/0295039 A1Massachusetts Institute of Technology
Most cited
By later US patents
- Receptor specific transepithelial transport of therapeutics240US 6,485,726 B1Brandeis University · 2002
- Receptor specific transepithelial transport of therapeutics214US 6,030,613 ABrandeis University · 2000
- Immunogenic polysaccharide-protein conjugates208US 4,356,170 ACanadian Patents and Development Limited · 1982
- Receptor specific transepithelial transport of immunogens207US 6,086,875 ABrandeis University · 2000
- Immunostimulatory polynucleotide/immunomodulatory molecule conjugates162US 6,610,661 B1The Regents of the University of California · 2003